PL3274710T3 - Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów - Google Patents

Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów

Info

Publication number
PL3274710T3
PL3274710T3 PL16716342T PL16716342T PL3274710T3 PL 3274710 T3 PL3274710 T3 PL 3274710T3 PL 16716342 T PL16716342 T PL 16716342T PL 16716342 T PL16716342 T PL 16716342T PL 3274710 T3 PL3274710 T3 PL 3274710T3
Authority
PL
Poland
Prior art keywords
cells
epithinal
rpe
potential
determination
Prior art date
Application number
PL16716342T
Other languages
English (en)
Inventor
Irina V. Klimanskaya
Julie Kathryn CARSON
Roger GAY
Yordanka Gikova IVANOVA
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of PL3274710T3 publication Critical patent/PL3274710T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6486Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
PL16716342T 2015-03-23 2016-03-23 Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów PL3274710T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136660P 2015-03-23 2015-03-23
PCT/US2016/023839 WO2016154357A1 (en) 2015-03-23 2016-03-23 Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP16716342.7A EP3274710B1 (en) 2015-03-23 2016-03-23 Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors

Publications (1)

Publication Number Publication Date
PL3274710T3 true PL3274710T3 (pl) 2021-12-27

Family

ID=55752717

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21167900.6T PL3869195T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy potencjału oddziaływania ludzkich komórek nabłonka barwnikowego siatkówki (RPE) i fotoreceptorów progenitorowych
PL16716342T PL3274710T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy do oznaczania potencjału ludzkich komórek nabłonka barwnikowego siatkówki (rpe) i komórek progenitorowych fotoreceptorów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21167900.6T PL3869195T3 (pl) 2015-03-23 2016-03-23 Ulepszone testy potencjału oddziaływania ludzkich komórek nabłonka barwnikowego siatkówki (RPE) i fotoreceptorów progenitorowych

Country Status (16)

Country Link
US (3) US11422125B2 (pl)
EP (3) EP3274710B1 (pl)
JP (4) JP6902474B2 (pl)
KR (2) KR20230132893A (pl)
CN (3) CN118995872A (pl)
AU (3) AU2016235176B2 (pl)
CA (2) CA2980580C (pl)
DK (1) DK3274710T3 (pl)
ES (2) ES2877400T3 (pl)
HU (1) HUE054946T2 (pl)
IL (3) IL293110B2 (pl)
MX (2) MX395233B (pl)
PL (2) PL3869195T3 (pl)
PT (2) PT3274710T (pl)
SG (3) SG10201907918VA (pl)
WO (1) WO2016154357A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂
TW202130806A (zh) 2019-10-30 2021-08-16 安斯泰來再生醫藥協會 用於產生視網膜色素上皮細胞之方法
KR102452657B1 (ko) * 2020-09-09 2022-10-11 조선대학교 산학협력단 Noxa 단백질에서 유래한 펩타이드를 포함하는 세포외 소포 생산 촉진용 조성물 및 이를 이용한 세포외 소포의 생산 방법
DE102022103893A1 (de) * 2022-02-18 2023-08-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Membranvesikel, die einen spektroskopisch nachweisbaren Indikator beinhalten, und deren Verwendung in einem Verfahren zum Nachweis der Phagozytose-Funktion bei biologischen Zellen

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
WO2007019398A1 (en) 2005-08-03 2007-02-15 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
AU782286B2 (en) 1999-06-30 2005-07-14 Advanced Cell Technology, Inc. Cytoplasmic transfer to de-differentiate recipient cells
US20040180430A1 (en) 1999-09-07 2004-09-16 West Michael D. Methods of restoring telomere length and extending cell lifespan using nuclear transfer
US20050255596A1 (en) 1999-09-07 2005-11-17 West Michael D Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer
CN1377424A (zh) 1999-09-07 2002-10-30 先进细胞技术公司 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长
WO2001032015A1 (en) 1999-11-02 2001-05-10 University Of Massachusetts, As Represented By Its Amherst Campus Use of haploid genomes for genetic diagnosis, modification and multiplication
CA2394812A1 (en) 1999-12-20 2001-06-28 Anthony C.F. Perry A method to produce cloned embryos and adults from cultured cells
MXPA02006093A (es) 1999-12-20 2004-08-23 Univ Massachusetts Celulas tipo madre o embrionicas producidas por transplante nuclear de especies de cruza.
WO2002072762A2 (en) 2001-03-08 2002-09-19 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
WO2002073188A1 (en) 2001-03-13 2002-09-19 Advanced Cell Technology, Inc. Method for generating replacement cells and/or tissues
MXPA04001725A (es) 2001-08-24 2005-04-11 Advanced Cell Tech Inc ANáLISIS DE SELECCION PARA IDENTIFICAR AGENTES INDUCTORES DE DIFERENCIACION Y PRODUCCION DE CELULAS DIFERENCIADAS PARA TERAPIA CELULAR.
US20050025750A1 (en) 2002-12-27 2005-02-03 Fissore Rafael A. Sperm-induced cellular activation
NZ548623A (en) 2004-01-02 2010-04-30 Advanced Cell Tech Inc Novel culture systems for ex vivo development of stem cells in telolecithal or eutelolecithal eggs
EP2929782A1 (en) 2004-01-23 2015-10-14 Ocata Therapeutics, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
GB0407836D0 (en) 2004-04-06 2004-05-12 Univ Cambridge Tech Fluorescent dyes and complexes
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US7838727B2 (en) 2004-11-04 2010-11-23 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
US20060263338A1 (en) 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
WO2006122005A2 (en) 2005-05-09 2006-11-16 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20090271335A1 (en) 2005-10-20 2009-10-29 Advanced Cell Technology, Inc. Totipotent, Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes
AU2007248412A1 (en) 2006-05-03 2007-11-15 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US8796021B2 (en) 2007-02-23 2014-08-05 Advanced Cell Technology, Inc. Blastomere culture to produce mammalian embryonic stem cells
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
WO2009085212A1 (en) 2007-12-19 2009-07-09 Advanced Cell Technology, Inc. Methods for producing pluripotent stem cell-generated embryos, and animals derived therefrom
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20120184035A1 (en) 2011-01-13 2012-07-19 Sadhana Agarwal Methods and Compositions For Reprogramming Cells
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
CA2858173C (en) 2011-12-06 2023-09-26 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
US9511152B2 (en) 2012-04-05 2016-12-06 The Board Of Regents Of The University Of Texas System Multicolored pH-activatable fluorescence nanoplatform
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP4292600A3 (en) * 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP3189135B1 (en) 2014-09-05 2021-06-02 Astellas Institute for Regenerative Medicine Retinal ganglion cells and progenitors thereof
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
CN108697641A (zh) 2015-08-18 2018-10-23 安斯泰来再生医药协会 临床制剂

Also Published As

Publication number Publication date
SG10201912315UA (en) 2020-02-27
IL293110B2 (en) 2023-11-01
SG11201707775TA (en) 2017-10-30
IL254617A0 (en) 2017-11-30
PT3869195T (pt) 2024-06-17
EP4343331A2 (en) 2024-03-27
US11422125B2 (en) 2022-08-23
IL293110B1 (en) 2023-07-01
US20180052150A1 (en) 2018-02-22
EP4343331A3 (en) 2024-06-19
AU2016235176A1 (en) 2017-10-26
CN113930476A (zh) 2022-01-14
MX395233B (es) 2025-03-25
WO2016154357A1 (en) 2016-09-29
EP3869195B1 (en) 2024-03-20
AU2022218516A1 (en) 2022-09-08
EP3274710A1 (en) 2018-01-31
JP6902474B2 (ja) 2021-07-14
MX2017012259A (es) 2018-05-17
CN107889507A (zh) 2018-04-06
CA2980580C (en) 2024-01-23
ES2877400T3 (es) 2021-11-16
ES2980659T3 (es) 2024-10-02
US20230408489A1 (en) 2023-12-21
IL293110A (en) 2022-07-01
SG10201907918VA (en) 2019-10-30
AU2022218516B2 (en) 2025-06-05
DK3274710T3 (da) 2021-09-06
EP3274710B1 (en) 2021-06-09
HUE054946T2 (hu) 2021-10-28
JP2021168655A (ja) 2021-10-28
KR20180011761A (ko) 2018-02-02
CN107889507B (zh) 2021-11-26
KR20230132893A (ko) 2023-09-18
JP7386206B2 (ja) 2023-11-24
AU2025226799A1 (en) 2025-11-06
IL254617B (en) 2022-06-01
PT3274710T (pt) 2021-07-06
JP2025183199A (ja) 2025-12-16
US11680941B2 (en) 2023-06-20
US20230051804A1 (en) 2023-02-16
JP2024037720A (ja) 2024-03-19
AU2016235176B2 (en) 2022-05-19
MX2022010736A (es) 2022-09-23
KR102577776B1 (ko) 2023-09-11
CA2980580A1 (en) 2016-09-29
CN113930476B (zh) 2024-11-12
CN118995872A (zh) 2024-11-22
IL303401A (en) 2023-08-01
PL3869195T3 (pl) 2024-07-22
CA3188112A1 (en) 2016-09-29
JP2018516535A (ja) 2018-06-28
EP3869195A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
IL282048A (en) Oxysterols and methods of use thereof
IL271275A (en) Compositions comprising curons and uses thereof
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
IL260878B (en) Integrated interactive application security testing
IL254039A0 (en) Anti-pvrig antibodies and methods of use
HUE058755T2 (hu) Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
IL254734B1 (en) Modified t cells and methods of making and using the same
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
IL251970B (en) Anti-cd79b antibodies and methods of use
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
MX384364B (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
IL269334A (en) Improved t cell compositions and methods
PT3215532T (pt) Anticorpos anti-tim3 e métodos de utilização
PT3548033T (pt) Compostos e respectivos métodos de utilização
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
EP3394065A4 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EP3303435A4 (en) HYDROFLUOROLEFINES AND METHOD OF USE THEREOF
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof